Alyftrek 10-50-125 MG tablet 14S
Ended Awarded
- Contract number
- SPE2DB26FX1LF
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $83,973
Award facts
- Contract value 100% obligated
- $83,973.24 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $83,973.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for ALYFTREK 10-50-125 mg tablets. This firm fixed-price delivery order was issued on November 6, 2025, with an ultimate completion date of November 7, 2025, with no set-aside designation. DMS Pharmaceutical Group is the sole prime contractor on this award, with no identified subcontractor relationships. The delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion government-wide acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through consistent performance on numerous delivery orders issued by the DLA's Medical Supply Chain division, with its product portfolio spanning branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The PPV-G GEN V IDC awarded to DMS Pharmaceutical Group carries a $500 million ceiling value and extends through December 31, 2036, featuring a 30-month base period with three additional 30-month option periods, positioning the company as a critical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DB26FX1LF?
SPE2DB26FX1LF was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 6, 2025.
How much is contract SPE2DB26FX1LF worth?
The government has obligated $83,973 on SPE2DB26FX1LF.
Is contract SPE2DB26FX1LF an order under another contract?
Yes. SPE2DB26FX1LF is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB26FX1LF competed?
The extent of competition for SPE2DB26FX1LF was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award